RSS

Helsinn Therapeutics

Swiss-based pharma group Helsinn has revealed its US subsidiary (Helsinn Therapeutics) has signed a co-promotion agreement with Novartis for Zykadia more

News

Kymab and Heptares Therapeutics have entered a strategic collaboration to discover, develop and commercialise novel antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology. more

News

Helsinn’s anamorelin HCI has been accepted for marketing authorisation application (MAA) review by the European Medicines Agency (EMA) more

News